Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Alcamí J[au]:

Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. Pernas M et al. J Virol. (2018)

Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. Coiras M et al. Expert Opin Drug Saf. (2017)

Potential role of tyrosine kinase inhibitors during primary HIV-1 infection. Ambrosioni J et al. Expert Rev Anti Infect Ther. (2017)

Search results

Items: 1 to 50 of 169

1.

Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients.

Ramírez de Arellano E, Díez-Fuertes F, Aguilar F, de la Torre Tarazona HE, Sánchez-Lara S, Lao Y, Vicario JL, García F, González-Garcia J, Pulido F, Gutierrez-Rodero F, Moreno S, Iribarren JA, Viciana P, Vilches C, Ramos M, Capa L, Alcamí J, Del Val M.

PLoS One. 2019 Aug 8;14(8):e0220459. doi: 10.1371/journal.pone.0220459. eCollection 2019.

2.

Association of a single nucleotide polymorphism in the ubxn6 gene with long-term non-progression phenotype in HIV-positive individuals.

Díez-Fuertes F, De La Torre-Tarazona HE, Calonge E, Pernas M, Bermejo M, García-Pérez J, Álvarez A, Capa L, García-García F, Saumoy M, Riera M, Boland-Auge A, López-Galíndez C, Lathrop M, Dopazo J, Sakuntabhai A, Alcamí J.

Clin Microbiol Infect. 2019 May 31. pii: S1198-743X(19)30274-5. doi: 10.1016/j.cmi.2019.05.015. [Epub ahead of print]

PMID:
31158522
3.

Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.

Sliepen K, Han BW, Bontjer I, Mooij P, Garces F, Behrens AJ, Rantalainen K, Kumar S, Sarkar A, Brouwer PJM, Hua Y, Tolazzi M, Schermer E, Torres JL, Ozorowski G, van der Woude P, de la Peña AT, van Breemen MJ, Camacho-Sánchez JM, Burger JA, Medina-Ramírez M, González N, Alcami J, LaBranche C, Scarlatti G, van Gils MJ, Crispin M, Montefiori DC, Ward AB, Koopman G, Moore JP, Shattock RJ, Bogers WM, Wilson IA, Sanders RW.

Nat Commun. 2019 May 29;10(1):2355. doi: 10.1038/s41467-019-10262-5.

4.

HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights.

Shacklett BL, Blanco J, Hightow-Weidman L, Mgodi N, Alcamí J, Buchbinder S, Chirenje M, Dabee S, Diallo M, Dumchev K, Herrera C, Levy ME, Martin Gayo E, Makoah NA, Mitchell KM, Mugwanya K, Reddy K, Rodríguez ML, Rodriguez-Garcia M, Shover CL, Shrivastava T, Tomaras G, Van Diepen M, Walia M, Warren M, Manrique A, Thyagarajan B, Torri T.

AIDS Res Hum Retroviruses. 2019 Jul;35(7):598-607. doi: 10.1089/AID.2019.0074. Epub 2019 May 29.

5.

HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study.

López-Huertas MR, Palladino C, Garrido-Arquero M, Esteban-Cartelle B, Sánchez-Carrillo M, Martínez-Román P, Martín-Carbonero L, Ryan P, Domínguez-Domínguez L, Santos IL, Moral SF, Benito JM, Rallón N, Alcamí J, Resino S, Fernández-Rodríguez A, Coiras M, Briz V; Multidisciplinary Group of viral coinfection HIV/Hepatitis (COVIHEP).

Sci Rep. 2019 Apr 3;9(1):5606. doi: 10.1038/s41598-019-41788-9.

6.

CCR5 structural plasticity shapes HIV-1 phenotypic properties.

Colin P, Zhou Z, Staropoli I, Garcia-Perez J, Gasser R, Armani-Tourret M, Benureau Y, Gonzalez N, Jin J, Connell BJ, Raymond S, Delobel P, Izopet J, Lortat-Jacob H, Alcami J, Arenzana-Seisdedos F, Brelot A, Lagane B.

PLoS Pathog. 2018 Dec 6;14(12):e1007432. doi: 10.1371/journal.ppat.1007432. eCollection 2018 Dec.

7.

Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.

Rosás-Umbert M, Llano A, Bellido R, Olvera A, Ruiz-Riol M, Rocafort M, Fernández MA, Cobarsi P, Crespo M, Dorrell L, Del Romero J, Alcami J, Paredes R, Brander C, Mothe B.

J Virol. 2019 Feb 5;93(4). pii: e01436-18. doi: 10.1128/JVI.01436-18. Print 2019 Feb 15.

8.

Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors.

Bermejo M, Ambrosioni J, Bautista G, Climent N, Mateos E, Rovira C, Rodríguez-Mora S, López-Huertas MR, García-Gutiérrez V, Steegmann JL, Duarte R, Cervantes F, Plana M, Miró JM, Alcamí J, Coiras M.

Biochem Pharmacol. 2018 Oct;156:248-264. doi: 10.1016/j.bcp.2018.08.031. Epub 2018 Aug 22.

PMID:
30142322
9.

Current situation of HIV research in Spain.

Alcamí J, Alemany A, Dodero J, Llibre JM.

Enferm Infecc Microbiol Clin. 2018 Sep;36 Suppl 1:26-30. doi: 10.1016/S0213-005X(18)30243-X. English, Spanish.

PMID:
30115404
10.

A small-molecule inhibitor of HIV-1 Rev function detected by a diversity screen based on RRE-Rev interference.

Prado S, Beltrán M, Moreno Á, Bedoya LM, Alcamí J, Gallego J.

Biochem Pharmacol. 2018 Oct;156:68-77. doi: 10.1016/j.bcp.2018.07.040. Epub 2018 Jul 31.

PMID:
30071201
11.

Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets.

Bedoya LM, Beltrán M, García-Pérez J, Obregón-Calderón P, Callies O, Jímenez IA, Bazzocchi IL, Alcamí J.

Front Pharmacol. 2018 Apr 18;9:358. doi: 10.3389/fphar.2018.00358. eCollection 2018.

12.

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, de Quirós JCLB, García F, Plana M; RISVAC02boost study.

PLoS One. 2018 Apr 10;13(4):e0195915. doi: 10.1371/journal.pone.0195915. eCollection 2018.

13.

Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.

Cascajero A, Rastrojo A, Díez-Fuertes F, Hernández-Novoa B, Aguado B, Moreno S, Alcami J, Pérez-Olmeda M.

J Virol. 2018 May 14;92(11). pii: e00390-18. doi: 10.1128/JVI.00390-18. Print 2018 Jun 1.

14.

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.

González N, McKee K, Lynch RM, Georgiev IS, Jimenez L, Grau E, Yuste E, Kwong PD, Mascola JR, Alcamí J.

PLoS One. 2018 Mar 20;13(3):e0193773. doi: 10.1371/journal.pone.0193773. eCollection 2018.

15.

Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers.

Benito JM, Ortiz MC, León A, Sarabia LA, Ligos JM, Montoya M, Garcia M, Ruiz-Mateos E, Palacios R, Cabello A, Restrepo C, Rodriguez C, Del Romero J, Leal M, Muñoz-Fernández MA, Alcamí J, García F, Górgolas M, Rallón N; ECRIS integrated in the Spanish AIDS Research Network.

BMC Med. 2018 Feb 28;16(1):30. doi: 10.1186/s12916-018-1026-6.

16.

Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.

Pernas M, Tarancón-Diez L, Rodríguez-Gallego E, Gómez J, Prado JG, Casado C, Dominguez-Molina B, Olivares I, Coiras M, León A, Rodriguez C, Benito JM, Rallón N, Plana M, Martinez-Madrid O, Dapena M, Iribarren JA, Del Romero J, García F, Alcamí J, Muñoz-Fernández M, Vidal F, Leal M, Lopez-Galindez C, Ruiz-Mateos E.

J Virol. 2018 Feb 12;92(5). pii: e01805-17. doi: 10.1128/JVI.01805-17. Print 2018 Mar 1.

17.

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, Plana M; RISVAC02boost study.

PLoS One. 2017 Oct 24;12(10):e0186602. doi: 10.1371/journal.pone.0186602. eCollection 2017. Erratum in: PLoS One. 2018 Apr 10;13(4):e0195915.

18.

Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum.

Martin GE, Alcami J, Spano JP, Ross AL.

J Virus Erad. 2017 Oct 1;3(4):236-241. No abstract available.

19.

MAZ induces MYB expression during the exit from quiescence via the E2F site in the MYB promoter.

Álvaro-Blanco J, Urso K, Chiodo Y, Martín-Cortázar C, Kourani O, Arco PG, Rodríguez-Martínez M, Calonge E, Alcamí J, Redondo JM, Iglesias T, Campanero MR.

Nucleic Acids Res. 2017 Sep 29;45(17):9960-9975. doi: 10.1093/nar/gkx641.

20.

Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells.

Sánchez-Del Cojo M, López-Huertas MR, Díez-Fuertes F, Rodríguez-Mora S, Bermejo M, López-Campos G, Mateos E, Jiménez-Tormo L, Gómez-Esquer F, Díaz-Gil G, Alcamí J, Coiras M.

PLoS One. 2017 Oct 2;12(10):e0185677. doi: 10.1371/journal.pone.0185677. eCollection 2017.

21.

Environmentally Friendly Procedure Based on Supercritical Fluid Chromatography and Tandem Mass Spectrometry Molecular Networking for the Discovery of Potent Antiviral Compounds from Euphorbia semiperfoliata.

Nothias LF, Boutet-Mercey S, Cachet X, De La Torre E, Laboureur L, Gallard JF, Retailleau P, Brunelle A, Dorrestein PC, Costa J, Bedoya LM, Roussi F, Leyssen P, Alcami J, Paolini J, Litaudon M, Touboul D.

J Nat Prod. 2017 Oct 27;80(10):2620-2629. doi: 10.1021/acs.jnatprod.7b00113. Epub 2017 Sep 19.

PMID:
28925702
22.

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.

López-Huertas MR, Jiménez-Tormo L, Madrid-Elena N, Gutiérrez C, Rodríguez-Mora S, Coiras M, Alcamí J, Moreno S.

Sci Rep. 2017 May 24;7(1):2385. doi: 10.1038/s41598-017-02634-y.

23.

Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection.

Coiras M, Ambrosioni J, Cervantes F, Miró JM, Alcamí J.

Expert Opin Drug Saf. 2017 May;16(5):547-559. doi: 10.1080/14740338.2017.1313224. Epub 2017 Apr 26. Review.

PMID:
28387147
24.

Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.

Ambrosioni J, Coiras M, Alcamí J, Miró JM.

Expert Rev Anti Infect Ther. 2017 May;15(5):421-423. doi: 10.1080/14787210.2017.1308823. Epub 2017 Mar 30. No abstract available.

PMID:
28322065
25.

5-Hydroxytyrosol inhibits HIV-1 replication in primary cells of the lower and upper female reproductive tract.

Saba E, Panina-Bordignon P, Pagani I, Origoni M, Candiani M, Doglioni C, Taccagni G, Ghezzi S, Alcami J, Vicenzi E, Poli G.

Antiviral Res. 2017 Jun;142:16-20. doi: 10.1016/j.antiviral.2017.03.003. Epub 2017 Mar 7.

PMID:
28286236
26.

Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-κB Pathways.

Olmedo DA, López-Pérez JL, Del Olmo E, Bedoya LM, Sancho R, Alcamí J, Muñoz E, Feliciano AS, Gupta MP.

Molecules. 2017 Feb 19;22(2). pii: E321. doi: 10.3390/molecules22020321.

27.

Different Expression of Interferon-Stimulated Genes in Response to HIV-1 Infection in Dendritic Cells Based on Their Maturation State.

Calonge E, Bermejo M, Diez-Fuertes F, Mangeot I, González N, Coiras M, Jiménez Tormo L, García-Perez J, Dereuddre-Bosquet N, Le Grand R, Alcamí J.

J Virol. 2017 Mar 29;91(8). pii: e01379-16. doi: 10.1128/JVI.01379-16. Print 2017 Apr 15.

28.

HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.

Dominguez-Molina B, Tarancon-Diez L, Hua S, Abad-Molina C, Rodriguez-Gallego E, Machmach K, Vidal F, Tural C, Moreno S, Goñi JM, Ramírez de Arellano E, Del Val M, Gonzalez-Escribano MF, Del Romero J, Rodriguez C, Capa L, Viciana P, Alcamí J, Yu XG, Walker BD, Leal M, Lichterfeld M, Ruiz-Mateos E; ECRIS integrated in the Spanish AIDS Research Network.

Clin Infect Dis. 2017 Mar 1;64(5):621-628. Epub 2016 Dec 16.

29.

An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies.

Martín V, Perales C, Fernández-Algar M, Dos Santos HG, Garrido P, Pernas M, Parro V, Moreno M, García-Pérez J, Alcamí J, Torán JL, Abia D, Domingo E, Briones C.

PLoS One. 2016 Dec 13;11(12):e0166902. doi: 10.1371/journal.pone.0166902. eCollection 2016.

30.

Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients.

Vanwalscappel B, Rato S, Perez-Olmeda M, Díez Fuertes F, Casartelli N, Alcami J, Mammano F.

Virology. 2017 Jan;500:247-258. doi: 10.1016/j.virol.2016.10.028. Epub 2016 Nov 15.

31.

Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity.

Bedoya LM, Beltrán M, Obregón-Calderón P, García-Pérez J, de la Torre HE, González N, Pérez-Olmeda M, Auñón D, Capa L, Gómez-Acebo E, Alcamí J.

AIDS. 2016 Nov 28;30(18):2767-2776.

32.

Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins.

Benureau Y, Colin P, Staropoli I, Gonzalez N, Garcia-Perez J, Alcami J, Arenzana-Seisdedos F, Lagane B.

J Virol Methods. 2016 Oct;236:184-195. doi: 10.1016/j.jviromet.2016.07.019. Epub 2016 Jul 20.

PMID:
27451265
33.

Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E.

J Virol. 2016 May 12;90(11):5231-5245. doi: 10.1128/JVI.00049-16. Print 2016 Jun 1.

34.

PKCθ and HIV-1 Transcriptional Regulator Tat Co-exist at the LTR Promoter in CD4(+) T Cells.

López-Huertas MR, Li J, Zafar A, Rodríguez-Mora S, García-Domínguez C, Mateos E, Alcamí J, Rao S, Coiras M.

Front Immunol. 2016 Feb 29;7:69. doi: 10.3389/fimmu.2016.00069. eCollection 2016.

35.

Analysis of Non-AIDS-Defining Events in HIV Controllers.

Dominguez-Molina B, Leon A, Rodriguez C, Benito JM, Lopez-Galindez C, Garcia F, Del Romero J, Gutierrez F, Viciana P, Alcami J, Leal M, Ruiz-Mateos E.

Clin Infect Dis. 2016 May 15;62(10):1304-1309. doi: 10.1093/cid/ciw120. Epub 2016 Mar 1.

PMID:
26936669
36.

IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle.

Coiras M, Bermejo M, Descours B, Mateos E, García-Pérez J, López-Huertas MR, Lederman MM, Benkirane M, Alcamí J.

Cell Rep. 2016 Mar 8;14(9):2100-2107. doi: 10.1016/j.celrep.2016.02.022. Epub 2016 Feb 25.

37.

Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen.

Prado S, Beltrán M, Coiras M, Bedoya LM, Alcamí J, Gallego J.

Biochem Pharmacol. 2016 May 1;107:14-28. doi: 10.1016/j.bcp.2016.02.007. Epub 2016 Feb 17.

PMID:
26896646
38.

Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.

Herrera C, Armanasco N, García-Pérez J, Ziprin P, Olejniczak N, Alcamí J, Nuttall J, Shattock RJ.

AIDS. 2016 Apr 24;30(7):1015-25. doi: 10.1097/QAD.0000000000001043.

39.

Rate and predictors of progression in elite and viremic HIV-1 controllers.

Leon A, Perez I, Ruiz-Mateos E, Benito JM, Leal M, Lopez-Galindez C, Rallon N, Alcami J, Lopez-Aldeguer J, Viciana P, Rodriguez C, Grau E, Iribarren J, Gatell JM, Garcia F; EC and Immune Pathogenesis Working group of the Spanish AIDS Research Network.

AIDS. 2016 May 15;30(8):1209-20. doi: 10.1097/QAD.0000000000001050.

PMID:
26854807
40.

Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells.

Bermejo M, López-Huertas MR, García-Pérez J, Climent N, Descours B, Ambrosioni J, Mateos E, Rodríguez-Mora S, Rus-Bercial L, Benkirane M, Miró JM, Plana M, Alcamí J, Coiras M.

Biochem Pharmacol. 2016 Apr 15;106:30-45. doi: 10.1016/j.bcp.2016.02.002. Epub 2016 Feb 4.

PMID:
26851491
41.

Functional Consequences for Apoptosis by Transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas/CD95 Alternative Splicing.

Montes M, Coiras M, Becerra S, Moreno-Castro C, Mateos E, Majuelos J, Oliver FJ, Hernández-Munain C, Alcamí J, Suñé C.

PLoS One. 2015 Oct 13;10(10):e0139812. doi: 10.1371/journal.pone.0139812. eCollection 2015.

42.

Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication.

Rodríguez-Mora S, Mateos E, Moran M, Martín MÁ, López JA, Calvo E, Terrón MC, Luque D, Muriaux D, Alcamí J, Coiras M, López-Huertas MR.

Retrovirology. 2015 Sep 16;12:78. doi: 10.1186/s12977-015-0203-3.

43.

A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.

Garcia-Perez J, Staropoli I, Azoulay S, Heinrich JT, Cascajero A, Colin P, Lortat-Jacob H, Arenzana-Seisdedos F, Alcami J, Kellenberger E, Lagane B.

Retrovirology. 2015 Jun 18;12:50. doi: 10.1186/s12977-015-0177-1.

44.

Involvement of the Rac1-IRSp53-Wave2-Arp2/3 Signaling Pathway in HIV-1 Gag Particle Release in CD4 T Cells.

Thomas A, Mariani-Floderer C, López-Huertas MR, Gros N, Hamard-Péron E, Favard C, Ohlmann T, Alcamí J, Muriaux D.

J Virol. 2015 Aug;89(16):8162-81. doi: 10.1128/JVI.00469-15. Epub 2015 May 27.

45.

Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina.

Callies O, Bedoya LM, Beltrán M, Muñoz A, Calderón PO, Osorio AA, Jiménez IA, Alcamí J, Bazzocchi IL.

J Nat Prod. 2015 May 22;78(5):1045-55. doi: 10.1021/np501025r. Epub 2015 Apr 30.

PMID:
25927586
46.

Negatively charged glyconanoparticles modulate and stabilize the secondary structures of a gp120 V3 loop peptide: toward fully synthetic HIV vaccine candidates.

Gianvincenzo PD, Calvo J, Perez S, Álvarez A, Bedoya LM, Alcamí J, Penadés S.

Bioconjug Chem. 2015 Apr 15;26(4):755-65. doi: 10.1021/acs.bioconjchem.5b00077. Epub 2015 Mar 11.

PMID:
25734507
47.

Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription.

Bermejo M, López-Huertas MR, Hedgpeth J, Mateos E, Rodríguez-Mora S, Maleno MJ, Plana M, Swindle J, Alcamí J, Coiras M.

Biochem Pharmacol. 2015 Apr 15;94(4):241-56. doi: 10.1016/j.bcp.2015.02.009. Epub 2015 Feb 27.

PMID:
25732195
48.

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.

Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, Puertas MC, Carrillo J, Gonzalez N, León A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernández C, Sánchez-Palomino S, Guardo AC, Peña J, Benito JM, Rallón N, Gómez CE, Perdiguero B, García-Arriaza J, Esteban M, López Bernaldo de Quirós JC, Brander C, García F; RISVAC-03 Study Group.

J Antimicrob Chemother. 2015;70(6):1833-42. doi: 10.1093/jac/dkv046. Epub 2015 Feb 26.

PMID:
25724985
49.

Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients.

Vidal F, Leal M, Alcamí J, Domingo P.

Pharmacogenomics. 2014 Apr;15(5):569-72. doi: 10.2217/pgs.14.1. No abstract available.

50.

Structure-based design of an RNA-binding p-terphenylene scaffold that inhibits HIV-1 Rev protein function.

González-Bulnes L, Ibáñez I, Bedoya LM, Beltrán M, Catalán S, Alcamí J, Fustero S, Gallego J.

Angew Chem Int Ed Engl. 2013 Dec 9;52(50):13405-9. doi: 10.1002/anie.201306665. Epub 2013 Nov 8. No abstract available.

PMID:
24214163

Supplemental Content

Loading ...
Support Center